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Abstract
Background: Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) antivenin is commonly recommended after pit
viper snakebites. Because copperhead envenomations are usually self-limited, some physicians are reluctant to use
this costly treatment routinely, while others follow a more liberal approach. We hypothesized that, in practice, only
patients with evidence of significant (moderate or severe) copperhead envenomation [those with snakebite severity
score (SSS) > 3] receive FabAV and examined a large cohort to determine the relationship between clinical findings
and FabAV administration.
Methods: All data from patients evaluated for copperhead snakebite at a rural tertiary referral center from 5/2002
to 10/2013 were compiled. Demographics, transfer status, antivenin use, and clinical findings were collected; SSS
was calculated. The relationships among FabAV use, clinical findings, and SSS were analyzed using t-test, chi-square,
and Pearson’s coefficient (p < 0.05 was significant).
Results: During the study period, 318 patients were treated for copperhead snakebite; 44 (13.8 %) received antivenin.
Median dose was four vials (range: 1–10; IQR: 4,6). There were no deaths. Most patients receiving FabAV (63.6 %) were
admitted. With regard to demographics and symptoms, only the degree of swelling (moderate vs. none/mild; p < 0.01)
and bite location (hand/arm vs. leg: p < 0.0001) were associated with FabAV use. A SSS > 3, indicating moderate or
severe envenomation, was only very weakly correlated with antivenin use (r = 0.217; p < 0.0001). The majority of
patients with SSS > 3 (65.8 %) did not receive antivenin while most patients who did receive antivenin (70.5 %) had
SSS≤ 3 (indicating mild envenomation).
Conclusions: Considerable variation occurs in antivenin administration after copperhead snakebite. Use of FabAV
appears poorly correlated with patients’ symptoms. This practice may expose patients to the risks of antivenin and
increasing costs of medical care without improving outcomes. Guidelines used for treating other pit viper strikes, such
as rattlesnake or cottonmouth snakebite may be too liberal for copperhead envenomations. Our data suggests that
most patients with mild or moderate envenomation appear to do well independent of FabAV use. We suggest, for
patients with copperhead snakebite, that consideration be given to withholding FabAV for those without clinical
evidence of severe envenomation until prospective randomized data are available.
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Background
Crotalid (pit viper) snakebites are common in the south-
ern United States during the warmer months. In East
Texas, and in most other regions of the country, those
from copperheads (Agkistrodon contortrix) are the most
common type of venomous snakebite. While copperhead
envenomations are typicallyself-limited, recommendations
by poison control centers and toxicologists often do not
discriminate between pit viper species in treatment algo-
rithms and commonly recommend polyvalent Crotalinae
ovine immune Fab (FabAV) antivenin for most crotalid
snakebites (rattlesnake, copperhead, and cottonmouth
species) [1–3]. Yet after copperhead snakebite, many
physicians are reluctant to use this very costly treatment
due to the often self-limited nature of that species’ enve-
nomations. Other clinicians, however, are concerned
about disregarding the advice of poison control center ex-
perts. As such, we have observed a significant practice
variation amongst emergency physicians and surgeons in
the region. We hypothesized that copperhead envenom-
ation is typically mild and self-limited and does not
require FabAV therapy. We sought to analyze outcomes
for a large series of patients struck by copperhead snakes
in East Texas with an emphasis on clinical presentation
and antivenin usage.
Methods
Approval was obtained, including waiver of consent,
from the East Texas Medical Center (ETMC) institu-
tional review board; emergency department registries
from our 450-bed regional tertiary care center were then
retrospectively queried for all patients evaluated for
acute venomous snakebite from 1/2002 to 12/2013
based on discharge diagnoses and ICD-9-CM codes
(E905.0). Only patients with documentation of distinct
fang marks were included in the analysis.
Snake species was reported based on patient accounts.
As victims are discouraged from hunting and killing
venomous snakes for identification, no other reliable
method exists for species confirmation. Copperhead spe-
cies are typically easily distinguished by the coloration,
markings, habitat, and other clues from other pit viper
species (rattlesnake and cottonmouth). Further, copper-
head species are, by far, the most common cause of
snakebite in the East Texas region [4].
Demographics, snake species, clinical findings, labora-
tory data and admission data, and antivenin use were
abstracted from the individual electronic charts includ-
ing those sent during from transferring facilities and
scanned into the electronic medical record.
Severity of envenomation
From the medical record, numbness, bruising, and
erythema were reported as present or absent. In contrast,
swelling and pain were described by degree – none (0),
mild (1), moderate (2), and severe (3) – based on
physician or nursing documentation. Coagulopathy
was assessed as any of the following: platelet count <
150,000/mm3; decrease in platelet count by > 25 %;
prothrombin time (PT) > 13.5 s; partial thromboplastin
time (PTT) > 40 s; fibrinogen level < 200 mg/dL. A pa-
tient was considered to have cardiovascular symptoms
if there was any evidence of hemodynamic comprom-
ise indicated by any of the following: systolic blood
pressure (SBP) < 90 mmHg; diastolic blood pressure
(DBP) < 50 mmHg; heart rate (HR) > 130 bpm or increase
in HR > 30 bpm during the assessment period. Constitu-
tional symptoms included any of the following: nausea,
vomiting, dizziness, fever, chills, or abdominal cramps/
pain. The snakebite severity score (SSS), a validated
research tool for assessing the severity of envenomation
after pit viper snakebite, which is also commonly included
in algorithms to determine the need for FabAV was calcu-
lated based on physician documentation and available
laboratory data [5–7]. The SSS is commonly interpreted
or grouped as mild (≤3), moderate (4–7), and severe (≥8).
Outcomes
Specific outcomes (admission status, length of stay,
complications, and mortality) were also compiled and
analyzed. Patients receiving FabAV were compared to
those who did not for individual clinical symptoms,
SSS and outcomes using t-test, Mann–Whitney U
test, and chi-square when appropriate. The degree of
envenomation (“mild” versus “moderate to severe”), as
indicated by the SSS > 3, was correlated to FabAV
administration using Pearson’s correlation. A p < 0.05
was considered significant for all statistical tests.
Results
Demographics
During the study period, 335 patients were evaluated for
venomous snakebite at ETMC; 318 (94.9 %) were known
or presumed copperhead snakebites. Of these, 123
(38.7 %) were initially evaluated at smaller hospitals or
clinics prior to transfer to ETMC. The age range was 2
to 89 years. Sixty-two patients (19.5 %) were children
(age < 18). Demographics are summarized in Table 1. No
specific demographic category was associated with
FabAV administration.
Clinical findings and FabAV Use
During the study period, 44 patients (13.8 %) received
FabAV antivenin. The median dose per patient was four
vials (range: 1–10; IQR: 4,6). Only five (8 %) of the 62
pediatric patients received antivenin. In 26 cases (59 %),
FabAV therapy was instituted at a smaller rural hospital
prior to transfer to ETMC.
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A comparison of clinical findings is summarized in
Table 2. Hemodynamic changes were significantly more
common in patients who received FabAV (p < 0.05), yet
these were only present in eight (18.2 %) of those
patients: seven patients had tachycardia while one
patient required vasopressor therapy. FabAV adminis-
tration was more common after upper extremity
snakebite (p < 0.0001) and in patients with moderate
swelling (p < 0.01); no patients were characterized as
having “severe” swelling. The presence or absence of
constitutional symptoms, numbness, bruising, and
erythema did not predict FabAV administration. Ab-
normal coagulation tests were present in 75 patients
(23.6 %) with no difference between those who did
and did not receive antivenin. Of these, 74 were mild
(grade 1) and one was moderate (grade 2) abnormal-
ities based on the SSS criteria. [5].
The calculated snakebite severity scores compared
to FabAV use are presented in Table 3. For the study
population, 280 patients (88 %) had mild envenom-
ation (SSS ≤ 3), 38 patients (12 %) had moderate enve-
nomations (SSS 4–7) and no patients had clinical
evidence of severe envenomation (SSS ≥ 8). The aver-
age calculated SSS was significantly higher in patients
who received FabAV (p < 0.001). However, the average
SSS in FabAV patients was still less than3 (2.8 ± 1.5);
median 2 (range: 1–7; IQR: 2,4). Based on SSS,
70.5 % of patients given FabAV sustained only mild
envenomation. Overall, SSS was poorly correlated
with FabAV administration (r = 0.238; p < 0.00002).
Table 1 Patient demographics
Total (318) FabAV (44) No FabAV (274) p
Age – years (mean ± SD) 37.4 ± 19.6 39.4 ± 18.3 37.2 ± 18.3 NS
Sex – % male 59.40 % 68 % 58 % NS
Interhospital transfer 123 (38.7 %) 26 (59.1 %) 97 (35.4)% <0.01
Hospital admission 80 (25.1 %) 33 (75 %) 47 (17.2 %) <0.0001
Hospital LOS 2.86 ± 1.13 2.84 ± 1.06 2.87 ± 1.17 NS
ICU admission 28 (35 %) 13 (39.4 %) 15 (31.2 %) NS
Table 2 Clinical findings
Bite location Total (318) FabAV (44) No FabAV (274) p
Upper (%) 130 (40.9 %) 35 (80 %) 95 (35 %) <0.0001
Lower (%) 185 (58.2 %) 9 (20 %) 176 (64 %)
Torso 3 (<1 %) 0 3 (<1 %)
Systemic symptoms
Cardiovascular symptoms 31 (9.7 %) 8 (18.2 %) 23 (8.4 %) <0.05
Constitutional symptoms 24 (17.3 %) 5 (11.4 %) 19 (6.9 %) NS
Abnormal coagulation tests 75 (23.6 %) 13 (29.5 %) 62(22.6 %) NS
Local symptoms
Numbness 19 (6.0 %) 4 (9.1 %) 15 (5.5 %) NS
Bruising 26 (8.2 %) 5 (11.4 %) 21 (7.7 %) NS
Erythema 112 (35.2 %) 16 (36.4 %) 96 (35.0 %) NS
Swelling – Degree
None (0) 50 (15.7 %) 1 (2.3 %) 49 (17.9 %) <0.005
Mild (1) 235 (73.9 %) 34 (77.3 %) 201 (73.4 %)
Moderate (2) 33 (10.4 %) 9 (20.5 %) 24 (8.8 %)
Severe (3) 0 0 0
Median (IQR) 1 (1,1) 1 (1,1) 1 (1,1)
Pain – Degree
Mild (1) 254 (79.9 %) 38 (86.4 %) 216 (78.9 %) NS
Moderate (2) 49 (15.4 %) 3 (6.8 %) 46 (16.8 %)
Severe (3) 15 (4.7 %) 3 (6.8 %) 12 (4.4 %)
Median (IQR) 1 (1,1) 1 (1,1) 1 (1,1)
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Further, most patients with SSS > 3 (25 of 38) did not
receive FabAV. As a predictor of FabAV administra-
tion, the category “SSS >3”, was also very poorly
correlated with its use (r = 0.217; p < 0.0001).
There were no deaths. Most patients given antivenin
(75 %) were admitted to the hospital; among those not
receiving FabAV, 17.2 % were admitted and observed.
Length of stay and intensive care unit admissions were
similar among admitted patients. No patients developed
compartment syndrome or required any surgical proce-
dures after copperhead snakebite. There were no wound
infections nor were there any reported or observed reac-
tions to FabAV in the study population.
Discussion
In the present study, we analyzed the management of
copperhead snakebite at a tertiary referral center in East
Texas with an emphasis on the use of FabAV and the
clinical indications for its use. We report a significant
variation in practice regarding FabAV administration.
While most patients, even those with moderate en-
venomation, were managed without receiving FabAV, the
majority of patients who did receive FabAV only had
clinical evidence of mild envenomation. Three-fourths of
patients who received FabAV were admitted to the
hospital, presumably to monitor for adverse reactions to
the antivenin rather than their degree of envenomation.
The snakebite severity score, a validated research tool
which is also often used to determine the need for anti-
venin therapy [2, 5], only poorly correlated with FabAV
use indicating that degree of envenomation was not the
primary factor driving the decision to administer anti-
venin after copperhead snakebite. Further, we demon-
strate a low overall degree of envenomation after
copperhead snakebite for a large cohort of patients.
Our findings reflect those of other authors who have
concluded that snakebite from known or presumed
copperhead pit vipers rarely require antivenin therapy
[1, 8, 9]. While local symptoms such as swelling and
bruising can be alarming after copperhead snakebite,
severe envenomations with systemic manifestations such
as shock, clinical bleeding from coagulopathy, respira-
tory failure, or death are essentially unheard of outside
of an intravenous envenomation or an anaphylactic reac-
tion to the venom (which is not treated principally with
antivenin but rather also with steroids, antihistamines,
etc.) [10–15].
More importantly, the present study confirms other
reports stating that often little clinical evidence, or stan-
dardized guidelines, drive costly FabAV administration
after copperhead snakebite [13]. While other retrospect-
ive studies have demonstrated that FabAV can limit the
progression of local tissue effects after copperhead en-
venomation, there is currently no data to suggest that
the cost and risk associated with FabAV improves long-
term limb function or leads to any other measurable
outcome improvements in these patients [11].
Although only 44 of 318 patients received FabAV in
our series, it is likely that very few, if any, of these pa-
tients actually required antivenin therapy based on their
clinical presentation as documented in the medical rec-
ord. As such, it appears that these patients realized little
or no benefit from receiving the drug. While certainly
the FabAV itself could have prevented recipients from
evolving more severe symptoms, the overall benign
initial presentations suggest otherwise.
These data suggest that some physicians treat patients
with FabAV independent of severity of envenomation.
Whether the cause is a lack of experience or education,
medico-legal fears, or a reliance on algorithms meant for
rattlesnake/cottonmouth envenomations, the overuse of
FabAV after copperhead snakebite must be addressed.
While the risks of the medication itself are relatively low
(8 % hypersensitivity and 13 % serum sickness), cost is
certainly a factor: each vial has a wholesale cost of ap-
proximately $2000 and patients may be charged as much
as $20,000 per vial for the antivenin alone [1, 16, 17]. With
a four-vial initial dose, plus hospital admission and other
costs such as interhospital transfer, medical bills can
quickly mount up – all with marginal proven benefit.
Interestingly, copperhead snakebites were completely
excluded from the initial clinical trials involving FabAV
and all prospective data regarding outcomes is based on
rattlesnake envenomations which are clearly much more
dangerous [11, 13, 18]. This fact, coupled with other case
series also documenting significant practice variation and
questionable clinical benefit, has led to the rare decision
by researchers to undertake a post-marketing double-
blind placebo-controlled randomized clinical trial
(RCT) comparing FabAV to placebo after copperhead
Table 3 Snakebite severity score
Snakebite severity score Total (318) FabAV (44) No FabAV (274) p
Mild (≤3) 280 (88.1 %) 31 (70.5 %) 249 (90.9 %) <0.001
Moderate (4–7) 38 (22.9 %) 13 (29.5 %) 25 (9 %)
Severe (≥8) 0 0 0
Mean ± SD 2.1 ± 1.2 2.8 ± 1.5 2.0 ± 1.1 <0.0001
Median (IQR) 2 (1,3) 2 (2,4) 2 (1,3)
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envenomation which is currently enrolling patients in
14 centers [1, 8, 11, 13, 19].
While the results of the RCT currently in progress
should provide much-needed guidance and will support
a standardized approach with regard to FabAV use for
copperhead snakebite, there does already appear to be
enough retrospective data, from this and previous studies,
to recommend using common sense, experience, and clin-
ical judgment to guide an expectant approach for mild to
moderate copperhead envenomations and to suggest that
definitive clinical findings indicating a severe envenom-
ation should be present before FabAV is given in most
patients [1, 8, 11]. Because management of copperhead
snakebite without antivenin treatment is well established
as safe, only patients likely to experience a tangible clinical
benefit should receive this costly drug [1, 8, 11, 20].
Automatic or standardized administration of FabAV for
copperhead snakebite should be discouraged.
Limitations
The main limitation of the present study is certainly
its retrospective nature. Reliance on medical record
descriptions of signs and symptoms of snakebite is
inadequate to truly judge the severity of envenom-
ation. Further, in the absence of prospective analysis,
patients were not evaluated consistently and not all
patients had adequate laboratory testing, especially
repeat testing. An additional limitation is our analysis
of a single institution’s experience creating a more
narrow perspective that a more regional analysis
might give. Although ETMC is a tertiary referral
center, and most patients who receive FabAV are
transferred in for “higher level of care services”,
some venomous snakebite patients are managed at
smaller local hospitals preventing their inclusion in
our analysis.
Conclusions
There is considerable variation in FabAV administration
after copperhead snakebite in East Texas – which reflects
the national experience. While current standardized
scoring guidelines (SSS > 3) for antivenin administration
are likely useful for rattlesnake and cottonmouth enveno-
mations, these criteria may be too liberal to guide treat-
ment after copperhead snakebite. Given the cost of
treatment, and the lack of proven clinical benefit, we
suggest, for patients with copperhead snakebite, that
consideration be given to withholding FabAV for those
without clinical evidence of severe envenomation. The
RCT, currently in progress, is clearly needed to clarify the
treatment algorithm and provide concrete guidelines for
physicians caring for copperhead snakebite victims.
Ethics approval
Approval was obtained, including waiver of consent, from
the East Texas Medical Center (ETMC) institutional
review board for this retrospective medical record query
(IRB protocol #674).
Abbreviations
SSS: snakebite severity score; FabAV: Crotalidae polyvalent immune Fab (ovine).
Competing interests
The authors declare that there are no competing interests.
Authors’ contributions
SCG, JAP and RC conceived and designed the present study. SCG, JAP and
LA were involved in data acquisition. SCG and VYD analyzed data and wrote
the initial draft of the manuscript. SCG, JAP, LA, RC and VYD contributed to
the critical revision. All authors read and approved the final manuscript.
Acknowledgments
The authors acknowledge the contributions of John Berne, MD and Katherine
O. Gale, MA for their reviews and editing services.
Author details
1Division of Trauma, Department of Surgery, East Texas Medical Center, Tyler,
TX, USA. 2Department of Emergency Medicine, East Texas Medical Center,
Tyler, TX, USA. 3Department of Surgery, Rutgers/RWJMS, New Brunswick, NJ,
USA. 4Director of Trauma Services, East Texas Medical Center, Level 1 Trauma
Center, 1020 E. Idel St., Tyler, TX 75701, USA.
Received: 1 September 2015 Accepted: 5 January 2016
References
1. Walker JP, Morrison RL. Current management of copperhead snakebite.
J Am Coll Surg. 2011;212(4):470–4. doi:10.1016/j.jamcollsurg.2010.12.049.
Discussion 474–5.
2. Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, et al.
Unified treatment algorithm for the management of crotaline snakebite in
the United States: results of an evidence-informed consensus workshop.
BMC Emerg Med. 2011;11:2. doi:10.1186/1471-227X-11-2.
3. Cribari C. Managment of poisonous snakebite. American College of
Surgeons (ACS). Committee on Trauma. 2004;1–4. https://www.facs.org/~/
media/files/quality%20programs/trauma/publications/snakebite.ashx.
Accessed 7 July 2014.
4. Werler J, Dixon J. Texas Snakes: Identification, distribution, and natural
history. Austin: University of Texas Press; 2000.
5. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the
assessment of crotalid snakebite. Ann Emerg Med. 1996;27(3):321–6.
6. Gross G, Gross O. Management of snakebites: study manual and guide for
health care professionals. Victoria, BC: Friesen Press; 2011.
7. Rothrock S. Tarascon Adult Emergency Pocketbook. 4th ed. Sudbury: Jones
and Bartlett; 2008.
8. Whitley RE. Conservative treatment of copperhead snakebites without
antivenin. J Trauma. 1996;41(2):219–21.
9. Keyler DE, Vandevoort JT. Copperhead envenomations: clinical profiles of
three different subspecies. Vet Hum Toxicol. 1999;41(3):149–52.
10. Scharman EJ, Noffsinger VD. Copperhead snakebites: clinical severity of local
effects. Ann Emerg Med. 2001;38(1):55–61. doi:10.1067/mem.2001.116148.
11. Lavonas EJ, Gerardo CJ, O’Malley G, Arnold TC, Bush SP, Banner Jr W, et al.
Initial experience with Crotalidae polyvalent immune Fab (ovine)
antivenom in the treatment of copperhead snakebite. Ann Emerg Med.
2004;43(2):200–6. doi:10.1016/S0196064403009296.
12. Walter FG, Stolz U, Shirazi F, Walter CM, McNally J. Epidemiology of the
reported severity of copperhead (Agkistrodon contortrix) snakebite. South
Med J. 2012;105(6):313–20. doi:10.1097/SMJ.0b013e318257c2d5.
13. Gerardo CJ, Lavonas EJ, McKinney RE. Ethical considerations in design of a
study to evaluate a US Food and Drug Administration-approved indication:
antivenom versus placebo for copperhead envenomation. Clin Trials.
2014;11(5):560–4. doi:10.1177/1740774514543538.
Gale et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:2 Page 5 of 6
14. Ali AJ, Horwitz DA, Mullins ME. Lack of coagulopathy after copperhead
snakebites. Ann Emerg Med. 2015;65(4):404–9. doi:10.1016/j.annemergmed.
2014.08.006.
15. Evans CS, Drake WG, Diskina M, Limkakeng AT, Gerardo CJ, Kopec KT, et al.
Hematologic abnormalities and bleeding in copperhead snakebite.
Wilderness Environ Med. 2014;25(1):116.
16. Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate
hypersensitivity reaction and serum sickness following administration of
Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg
Med. 2012;19(2):121–31. doi:10.1111/j.1553-2712.2011.01276.x.
17. Jester E. Snakebite treatment often complicated, costly. The Gainsville Sun.
2013. http://www.gainesville.com/article/20130612/articles/130619841.
18. Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, et al. A
randomized multicenter trial of crotalinae polyvalent immune Fab (ovine)
antivenom for the treatment for crotaline snakebite in the United States.
Arch Intern Med. 2001;161(16):2030–6.
19. BTG International I. A randomized, double-blind, placebo-controlled study
comparing CroFab versus placebo with rescue treatment for copperhead
snake envenomation (Copperhead RTC) [NCT01864200]. http://clinicaltrials.
gov/show/NCT01864200. Accessed Sept. 10, 2014.
20. Burch JM, Agarwal R, Mattox KL, Feliciano DV, Jordan Jr GL. The treatment
of crotalid envenomation without antivenin. J Trauma. 1988;28(1):35–43.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gale et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:2 Page 6 of 6
